If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
484.50    9.20 (1.94%)
Bid:
484.40
Ask:
484.60
Spread: 0.20 (0.041%)
Market Cap: £6.04b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

AGM TRADING UPDATE

29 Apr 2026 07:00

RNS Number : 2917C
Melrose Industries PLC
29 April 2026
 

29 April 2026

 

MELROSE INDUSTRIES PLC - AGM TRADING UPDATE

 

Ahead of its AGM today, Melrose Industries PLC ("Melrose"), a world-leading global aerospace and defence business, announces a trading update for the first quarter ended 31 March 2026 (the "Period"). All growth rates are stated at constant currency.

 

First quarter trading

 

Melrose has made a good start to the year, with a strong financial performance in the first quarter, alongside continued operational and commercial progress. Group revenue grew 11%, reflecting strong progress in Engines, up 20%, and Airframes up 4%. The combination of top line growth and margin progression resulted in adjusted operating profit for the Group and both divisions being well ahead of the same period last year.

 

Engines

 

The performance in Engines was driven by both OE and aftermarket with similar levels of growth in the Period in both segments. Within our RRSP portfolio, OE growth was particularly strong largely driven by deliveries for newer engines. In the aftermarket, all parts of the division delivered good growth with a particularly strong performance in our repairs and military businesses. 

 

Airframes

 

Within Airframes, Defence continues to perform well with double digit growth in the Period driven by our global portfolio. This was partially offset by Civil, where sales were slightly ahead of the comparative period, with good growth across business jets and widebody offset by lower narrowbody volumes, with the latter consistent with the broader market environment. 

 

Group net debt and free cash flow were in line with our expectations.

 

Middle East

The Group has no operating footprint in the Middle East and minimal direct supply chain exposure. While our hedging strategy for utility costs means the Group is well protected in 2026 from increases in energy prices, we are seeing some inflationary pressures in the form of higher freight costs. The potential impact on civil flying hours from reduced jet fuel availability and higher prices is uncertain, and will be dependent on the duration of the conflict.

 

 

Outlook for full year 2026

 

We continue to monitor and manage impacts from the Middle East, working closely with our customers and suppliers. Our guidance for the full year, which assumes no further material impact from the conflict, remains unchanged:

 

· Revenue of £3.75 billion to £3.95 billion

· Adjusted operating profit of £700 million to £750 million, reflecting an adjusted operating margin of c.19% at the mid-point

· Free cash flow generation of £150 million to £200 million (after interest and tax)

· In line with historical and industry seasonality, profit and cash will be second half weighted

· Guidance based on US$ = 1.37 average exchange rate

 

Melrose operates in end markets underpinned by attractive fundamentals, with proprietary technologies and established positions on all the world's leading aircraft. We have seen positive momentum in the first quarter and are well placed to deliver further growth and increased free cash flow in 2026 and the years ahead.

 

Melrose will publish its interim results for the first half ending 30 June 2026 on Friday 31 July 2026.

 

Enquiries:

 

Investor Relations:

Mat Wootton:

+44 (0) 7483 961 233, mat.wootton@melroseplc.net

 

Media:

Simon Sporborg, Tom Pigott / Brunswick:

+44 (0) 207 404 5959, melrose@brunswickgroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGZDNRLGVZM
Date   Source Headline
2nd Oct 20237:00 amRNSShare Buyback Programme
25th Sep 20234:00 pmRNSHolding(s) in Company
18th Sep 20237:00 amRNSHolding(s) in Company
12th Sep 20237:00 amRNSGTF PW1100G update
7th Sep 20237:00 amRNSHalf-year Report
5th Sep 20234:00 pmRNSHolding(s) in Company
1st Sep 20234:30 pmRNSHolding(s) in Company
14th Aug 20231:23 pmRNSHolding(s) in Company
11th Aug 20233:30 pmRNSHolding(s) in Company
8th Aug 20234:00 pmRNSHolding(s) in Company
27th Jul 20234:30 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSDirectorate Change
19th Jun 20237:00 amRNSHolding(s) in Company
16th Jun 20234:45 pmRNSDirectorate Change
16th Jun 20231:30 pmRNSHolding(s) in Company
14th Jun 20236:19 pmRNSDirector/PDMR Shareholding
13th Jun 20234:50 pmRNSHolding(s) in Company
9th Jun 202310:00 amRNSHolding(s) in Company
8th Jun 20231:15 pmRNSResult of AGM
2nd Jun 202310:30 amRNSHolding(s) in Company
18th May 20235:15 pmRNSDirector/PDMR Shareholding
18th May 20234:02 pmRNSDirector/PDMR Shareholding
17th May 20231:00 pmRNSCapital Markets Event & New 2025 Guidance
15th May 20237:00 amRNSHolding(s) in Company
11th May 20235:15 pmRNSHolding(s) in Company
10th May 20237:00 amRNSTrading Update & New Guidance
5th May 20237:00 amRNSHolding(s) in Company
4th May 20237:00 amRNSHolding(s) in Company
27th Apr 202311:05 amRNSHolding(s) in Company
25th Apr 20234:35 pmRNSAnnual Report and Notice of Annual General Meeting
21st Apr 20234:00 pmRNSPost-Offer Undertakings Announcement
20th Apr 202312:20 pmRNSHolding(s) in Company
20th Apr 202311:55 amRNSDirector/PDMR Shareholding
20th Apr 20238:14 amRNSCompletion of the demerger of Dowlais
18th Apr 202311:30 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSDirector Declaration
13th Apr 20235:30 pmRNSMelrose Industries
3rd Apr 20237:00 amRNSHolding(s) in Company
31st Mar 20234:00 pmRNSConfirmation of Post-Offer Undertakings
30th Mar 202311:45 amRNSResults of General Meeting
17th Mar 20235:15 pmRNSDirector Declaration
16th Mar 20232:00 pmRNSSecond Interim Dividend - Payment Date
6th Mar 20234:15 pmRNSHolding(s) in Company
3rd Mar 20234:10 pmRNSPublication of a Prospectus
3rd Mar 20234:00 pmRNSCirc re. Demerger Proposal
2nd Mar 20237:00 amRNSFinal Results
17th Feb 20235:00 pmRNSDirector Declaration
31st Jan 20239:45 amRNSHolding(s) in Company
20th Jan 202312:30 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSTrading Update & Capital Markets Event

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.